financetom
Business
financetom
/
Business
/
UnitedHealth, Amedisys Extend Merger Deadline Amid Regulatory Scrutiny
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
UnitedHealth, Amedisys Extend Merger Deadline Amid Regulatory Scrutiny
Dec 27, 2024 8:47 AM

11:29 AM EST, 12/27/2024 (MT Newswires) -- UnitedHealth Group ( UNH ) and Amedisys ( AMED ) agreed to extend the deadline of their proposed merger as the deal faces scrutiny from the US Department of Justice over competition concerns.

UnitedHealth ( UNH ), through its Optum subsidiary, agreed in June 2023 to acquire home health and hospice services provider Amedisys ( AMED ) for $101 per share in cash. The deal requires regulatory approval to be completed.

Last month, the Justice Department, along with the attorneys general of Maryland, Illinois, New Jersey and New York, filed a lawsuit in Maryland against the planned transaction over competition concerns.

The companies have now agreed to extend the deal's completion deadline to 10 days after a final court decision is issued in the DOJ lawsuit or Dec. 31, 2025, whichever is earlier, Amedisys ( AMED ) said in a filing with the Securities and Exchange Commission.

The companies previously expected the transaction to close by Dec. 27, Reuters reported.

The new waiver agreement includes a regulatory break fee of $275 million, which may increase to up to $325 million if the companies fail to divest certain assets to gain approval, the latest filing showed. "Certain closing conditions relating to government approvals are no longer conditions to the consummation of the merger," according to the filing.

UnitedHealth ( UNH ) didn't respond to a request for comment by MT Newswires. Shares of the health insurer edged down 0.4% in Friday trading, while Amedisys' ( AMED ) gained 4.5%.

"We are challenging this merger because home health and hospice patients and their families experiencing some of the most difficult moments of their lives deserve affordable, high quality care options," US Attorney General Merrick Garland said in a Nov. 12 statement. "The Justice Department will not hesitate to check unlawful consolidation and monopolization in the healthcare market that threatens to harm vulnerable patients, their families, and health care workers."

Price: 89.83, Change: +3.88, Percent Change: +4.51

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Flat to Higher Premarket Wednesday
Sector Update: Consumer Stocks Flat to Higher Premarket Wednesday
Dec 11, 2024
09:09 AM EST, 12/11/2024 (MT Newswires) -- Consumer stocks were flat to higher premarket Wednesday, with The Consumer Staples Select Sector SPDR Fund ( XLP ) inactive and The Consumer Discretionary Select Sector SPDR Fund ( XLY ) up 0.8%. Macy's (M) shares were down 11% after the company reported lower fiscal Q3 adjusted earnings and revenue in addition to...
New Fortress Energy Signs 10-Year Charter Deal With Egyptian Natural Gas
New Fortress Energy Signs 10-Year Charter Deal With Egyptian Natural Gas
Dec 11, 2024
09:07 AM EST, 12/11/2024 (MT Newswires) -- New Fortress Energy ( NFE ) said Wednesday it has signed a 10-year charter agreement with Egyptian Natural Gas Holding for Energos Eskimo, a 160,000 cubic meter floating storage and regasification unit. The unit will be deployed to Egyptian Natural Gas' LNG import terminal in Ain Sokhna, Egypt, and is expected to start...
CareDx, TC BioPharm Collaborate to Use AlloCell Test for Achieve Trial
CareDx, TC BioPharm Collaborate to Use AlloCell Test for Achieve Trial
Dec 11, 2024
09:07 AM EST, 12/11/2024 (MT Newswires) -- CareDx ( CDNA ) and TC Biopharm ( TCBP ) said Wednesday they have struck a partnership under which CareDx ( CDNA ) will carry out pharmacokinetic analysis through its AlloCell test in the Achieve clinical study of allogeneic gamma delta T cell therapy TCB008. Financial terms weren't disclosed. The trial will evaluate...
Why Dave & Buster's Entertainment Stock Is Tumbling Wednesday
Why Dave & Buster's Entertainment Stock Is Tumbling Wednesday
Dec 11, 2024
Dave & Buster’s Entertainment Inc shares are trading lower Wednesday after the company reported worse-than-expected financial results for the third quarter and announced a CEO transition. Multiple analysts downgraded the stock following the print. Q3 Revenue: $453 million, versus analyst estimates of $563.6 million Q3 Adjusted EPS: Loss of 45 cents, versus estimates of 90 cents Total revenue decreased 3%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved